We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation.
- Authors
Kuznar, Wayne
- Abstract
The article discusses clinical trials which shows ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Topics discussed include improvement in progression-free survival; oral therapeutic with a noncytotoxic mechanism of action in advanced IDH1-mutant cholangiocarcinoma; and rise in blood bilirubin level.
- Subjects
CHOLANGIOCARCINOMA; GENETIC counseling; HEMOPHILIACS
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p18
- ISSN
2164-4403
- Publication type
Article